Hydroxychloroquine trial suspended by WHO

Amy Baxter | | Health Exec | Management

The World Health Organization has suspended the trial of the controversial drug hydroxychloroquine due to safety concerns, Axios reported. The report comes just a few weeks after President Trump announced he had been taking the drug as a preventative measure against infection of COVID-19.

Hydroxychloroquine has been touted by Trump as a treatment for COVID-19, though evidence that the drug, which is typically used to treat malaria, is effective against COVID-19 has not been proven. The FDA has also issued a warning that the drug should only be administered in hospitals due to the heart risks.

WHO decided to shut down its trial of the drug as a COVID-19 treatment after patients who took it were more likely to die or develop irregular heart rhythm and potentially sudden cardiac death than those who did nothing. Those findings were recently published in The Lancet, which reviewed 96,000 hospitalized COVID-19 patients in six continents between Dec. 20, 2019 and April 14, 2020.

See the full story below:

WHO temporarily suspends trial of hydroxychloroquine over safety concerns

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.